nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ABCB1—Topotecan—cervical cancer	0.545	0.625	CbGbCtD
Propranolol—CYP3A4—Topotecan—cervical cancer	0.327	0.375	CbGbCtD
Propranolol—ADRB3—female reproductive system—cervical cancer	0.00929	0.0818	CbGeAlD
Propranolol—ADRB3—female gonad—cervical cancer	0.00845	0.0744	CbGeAlD
Propranolol—SLC22A2—renal system—cervical cancer	0.00697	0.0614	CbGeAlD
Propranolol—ORM1—endometrium—cervical cancer	0.0052	0.0458	CbGeAlD
Propranolol—ORM1—female reproductive system—cervical cancer	0.00431	0.0379	CbGeAlD
Propranolol—HTR1A—renal system—cervical cancer	0.00407	0.0358	CbGeAlD
Propranolol—HTR1B—female reproductive system—cervical cancer	0.00404	0.0356	CbGeAlD
Propranolol—ADRB1—female reproductive system—cervical cancer	0.0038	0.0335	CbGeAlD
Propranolol—CYP1A1—epithelium—cervical cancer	0.0033	0.029	CbGeAlD
Propranolol—CYP1A1—uterine cervix—cervical cancer	0.00327	0.0288	CbGeAlD
Propranolol—CYP3A5—uterine cervix—cervical cancer	0.0032	0.0282	CbGeAlD
Propranolol—CYP1A2—renal system—cervical cancer	0.0031	0.0273	CbGeAlD
Propranolol—CYP1A1—renal system—cervical cancer	0.00306	0.0269	CbGeAlD
Propranolol—CYP3A5—renal system—cervical cancer	0.00299	0.0263	CbGeAlD
Propranolol—CYP1A1—mammalian vulva—cervical cancer	0.00286	0.0252	CbGeAlD
Propranolol—CYP2C19—vagina—cervical cancer	0.00275	0.0242	CbGeAlD
Propranolol—CYP1A1—uterus—cervical cancer	0.00273	0.024	CbGeAlD
Propranolol—ORM1—lymph node—cervical cancer	0.00252	0.0222	CbGeAlD
Propranolol—CYP1A1—female reproductive system—cervical cancer	0.00245	0.0216	CbGeAlD
Propranolol—CYP3A4—renal system—cervical cancer	0.00225	0.0198	CbGeAlD
Propranolol—CYP1A1—female gonad—cervical cancer	0.00223	0.0196	CbGeAlD
Propranolol—CYP1A1—vagina—cervical cancer	0.00222	0.0195	CbGeAlD
Propranolol—CYP2D6—renal system—cervical cancer	0.00221	0.0195	CbGeAlD
Propranolol—CYP3A5—female gonad—cervical cancer	0.00218	0.0192	CbGeAlD
Propranolol—CYP3A5—vagina—cervical cancer	0.00217	0.0191	CbGeAlD
Propranolol—CYP3A4—female reproductive system—cervical cancer	0.0018	0.0158	CbGeAlD
Propranolol—CYP2D6—female reproductive system—cervical cancer	0.00177	0.0156	CbGeAlD
Propranolol—ABCB1—epithelium—cervical cancer	0.00171	0.0151	CbGeAlD
Propranolol—ABCB1—uterine cervix—cervical cancer	0.0017	0.015	CbGeAlD
Propranolol—ABCB1—decidua—cervical cancer	0.00162	0.0142	CbGeAlD
Propranolol—CYP2D6—female gonad—cervical cancer	0.00161	0.0142	CbGeAlD
Propranolol—ABCB1—renal system—cervical cancer	0.00159	0.014	CbGeAlD
Propranolol—ABCB1—endometrium—cervical cancer	0.00154	0.0135	CbGeAlD
Propranolol—ABCB1—mammalian vulva—cervical cancer	0.00149	0.0131	CbGeAlD
Propranolol—CYP1A1—lymph node—cervical cancer	0.00143	0.0126	CbGeAlD
Propranolol—ABCB1—uterus—cervical cancer	0.00142	0.0125	CbGeAlD
Propranolol—Rash erythematous—Topotecan—cervical cancer	0.00141	0.0946	CcSEcCtD
Propranolol—ABCB1—female reproductive system—cervical cancer	0.00127	0.0112	CbGeAlD
Propranolol—ABCB1—female gonad—cervical cancer	0.00116	0.0102	CbGeAlD
Propranolol—ABCB1—vagina—cervical cancer	0.00115	0.0101	CbGeAlD
Propranolol—Anaphylactoid reaction—Topotecan—cervical cancer	0.000809	0.0543	CcSEcCtD
Propranolol—Lethargy—Topotecan—cervical cancer	0.000799	0.0536	CcSEcCtD
Propranolol—ABCB1—lymph node—cervical cancer	0.000745	0.00656	CbGeAlD
Propranolol—Cardiac arrest—Topotecan—cervical cancer	0.000744	0.05	CcSEcCtD
Propranolol—Neutropenia—Topotecan—cervical cancer	0.000633	0.0425	CcSEcCtD
Propranolol—Infestation NOS—Topotecan—cervical cancer	0.000603	0.0405	CcSEcCtD
Propranolol—Infestation—Topotecan—cervical cancer	0.000603	0.0405	CcSEcCtD
Propranolol—Pharyngitis—Topotecan—cervical cancer	0.000537	0.0361	CcSEcCtD
Propranolol—Alopecia—Topotecan—cervical cancer	0.000478	0.0321	CcSEcCtD
Propranolol—Cough—Topotecan—cervical cancer	0.000411	0.0276	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000399	0.0268	CcSEcCtD
Propranolol—Anaphylactic shock—Topotecan—cervical cancer	0.000385	0.0258	CcSEcCtD
Propranolol—Infection—Topotecan—cervical cancer	0.000382	0.0257	CcSEcCtD
Propranolol—Nervous system disorder—Topotecan—cervical cancer	0.000377	0.0253	CcSEcCtD
Propranolol—Skin disorder—Topotecan—cervical cancer	0.000374	0.0251	CcSEcCtD
Propranolol—Paraesthesia—Topotecan—cervical cancer	0.000345	0.0232	CcSEcCtD
Propranolol—Dyspnoea—Topotecan—cervical cancer	0.000343	0.023	CcSEcCtD
Propranolol—Dyspepsia—Topotecan—cervical cancer	0.000339	0.0227	CcSEcCtD
Propranolol—Decreased appetite—Topotecan—cervical cancer	0.000334	0.0225	CcSEcCtD
Propranolol—Gastrointestinal disorder—Topotecan—cervical cancer	0.000332	0.0223	CcSEcCtD
Propranolol—Fatigue—Topotecan—cervical cancer	0.000332	0.0223	CcSEcCtD
Propranolol—Pain—Topotecan—cervical cancer	0.000329	0.0221	CcSEcCtD
Propranolol—Constipation—Topotecan—cervical cancer	0.000329	0.0221	CcSEcCtD
Propranolol—Gastrointestinal pain—Topotecan—cervical cancer	0.000315	0.0211	CcSEcCtD
Propranolol—Urticaria—Topotecan—cervical cancer	0.000306	0.0205	CcSEcCtD
Propranolol—Abdominal pain—Topotecan—cervical cancer	0.000304	0.0204	CcSEcCtD
Propranolol—Body temperature increased—Topotecan—cervical cancer	0.000304	0.0204	CcSEcCtD
Propranolol—Hypersensitivity—Topotecan—cervical cancer	0.000283	0.019	CcSEcCtD
Propranolol—Asthenia—Topotecan—cervical cancer	0.000276	0.0185	CcSEcCtD
Propranolol—Diarrhoea—Topotecan—cervical cancer	0.000263	0.0177	CcSEcCtD
Propranolol—Dizziness—Topotecan—cervical cancer	0.000254	0.0171	CcSEcCtD
Propranolol—Vomiting—Topotecan—cervical cancer	0.000245	0.0164	CcSEcCtD
Propranolol—Rash—Topotecan—cervical cancer	0.000243	0.0163	CcSEcCtD
Propranolol—Dermatitis—Topotecan—cervical cancer	0.000242	0.0163	CcSEcCtD
Propranolol—Nausea—Topotecan—cervical cancer	0.000229	0.0153	CcSEcCtD
